The agreement positions Bristol-Myers to develop subcutaneous formulations of molecules against PD-1 and 10 other immuno-oncology targets.

The deal gives Boehringer access to Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.

Janssen is ending a license deal with MacroGenics for duvortuxizumab, a CD19- and CD3-targeting drug for B-cell malignancies.

Daiichi Sankyo has cut and run from its $650 million pain alliance with Charleston Laboratories seven months after receiving a CRL.

The deal sees Takeda commit to paying AstraZeneca up to $400 million for the chance to co-develop the alpha-synuclein antibody.

Samsung is taking its first steps beyond the lower risk, lower reward world of biosimilars by teaming up with Takeda to co-develop drugs.

The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.

Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.

The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.

Takeda's R&D shake-up continues to rumble on, with the Japanese drugmaker signing a wide-ranging deal that will see it work closely with researchers…